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Key points 
 
 The prevalence of antiepileptic drug prescribing before, during and after pregnancy 
varies between different regions of Europe. 
 
 Within Europe, variations exist in the specific antiepileptic drugs most commonly 
prescribed. 
 
 Evidence that a proportion of AED prescriptions are being stopped during pregnancy 
rather than before pregnancy, as well as low levels of folic acid co-prescribing, 
suggests that many pregnancies are either unplanned or that full preconception care 
is not received by many women. 
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Abstract  
 
Purpose To explore antiepileptic drug (AED) prescribing before, during and after pregnancy 
as recorded in seven population-based electronic healthcare databases.   
 
Methods Databases in Denmark, Norway, the Netherlands, Italy (Emilia Romagna/Tuscany), 
Wales, and the Clinical Practice Research Datalink, representing the rest of the UK, were 
accessed for the study. Women with a pregnancy starting and ending between 2004 and 
2010, which ended in a delivery, were identified. AED prescriptions issued (UK) or dispensed 
(non-UK) at any time during pregnancy and the 6 months before and after pregnancy were 
identified in each of the databases. AED prescribing patterns were analysed and the choice 
of AEDs and co-prescribing of folic acid were evaluated. 
 
Results In total, 978,957 women with 1,248,713 deliveries were identified. In all regions, 
AED prescribing declined during pregnancy and was lowest during the third trimester, 
before returning to pre-pregnancy levels by 6 months following delivery. For all deliveries, 
the prevalence of AED prescribing during pregnancy was 51 per 10,000 pregnancies (CI9549-
52) and was lowest in the Netherlands (43/10,000 CI9533-54) and highest in Wales 
(60/10,000 CI9554-66). In Denmark, Norway and the two UK databases lamotrigine was the 
most commonly prescribed AED, whereas in the Italian and Dutch databases 
carbamazepine, valproate and phenobarbital were most frequently prescribed. Few women 
prescribed AEDs in the 3 months before pregnancy were co-prescribed high dose folic acid: 
ranging from 1.0% (CI950.3-1.8) in Emilia Romagna to 33.5% (CI9528.7-38.4) in Wales. 
 
Conclusion The country differences in prescribing patterns may suggest different use, 
knowledge or interpretation of the scientific evidence base. The low co-prescribing of folic 
acid indicates that more needs to be done to better inform clinicians and women of 
childbearing age taking AEDs about the need to offer and receive complete preconception 
care. 
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Introduction  
 
The older antiepileptic drugs (AEDs), when taken during early pregnancy, are associated 
with a risk of major congenital anomalies two to three times greater than that of the general 
population,[1, 2] although this varies with AED.[3, 4] Sodium valproate has also been associated 
with impaired cognitive function and developmental delay in the offspring.[5] The 
teratogenic effects outside the epilepsy indication are uncertain, but it is advised to take a 
precautionary approach. Over the last two decades a number of new AEDs have been 
introduced and, for some, the safety profiles indicate a lower risk of teratogenicity,[6] whilst 
for others they are yet to be fully determined.[7, 8] 
 
Three to four pregnancies in every thousand involve women with epilepsy.[9] The risk of 
seizure recurrence means it is often not appropriate to discontinue treatment, and some 
women require more than one AED (polytherapy) to obtain optimum seizure control. As 
some AEDs are more effective than others at controlling particular types of seizures, with 
risks to both mother and fetus from poor seizure control, it is not always possible to 
prescribe pregnant women the product with the most favourable safety profile in relation to 
teratogenicity.[10]  
 
In addition to epilepsy, some AEDs are licensed or prescribed off-label to treat other 
conditions including trigeminal neuralgia, neuropathic pain and as prophylaxis of bipolar 
disorder, migraine, depression and generalised anxiety disorders.[11] Women taking AEDs 
are recommended to take folic acid prior to conception and in the first trimester, as some 
AEDs may alter folate metabolism or absorption.[12] This study aimed to assess the extent 
and nature of AED prescribing, regardless of indication, during and around pregnancy in 
seven population-based electronic healthcare databases in Europe between 2004 and 2010. 
This study forms part of EUROmediCAT, a Seventh Framework Programme study funded by 
the European Commission that aims to make more systematic use of electronic healthcare 
databases in combination with EUROCAT congenital anomaly registry data[13] for 
reproductive safety evaluation. 
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Methods 
 
Setting 
Seven population-based electronic healthcare databases contributed to the study; two in 
Italy (Tuscany[14]/Emilia Romagna[15]), two in the United Kingdom (the Secure Anonymised 
Information Linkage Databank in Wales [16] and the UK-wide Clinical Practice Research 
Datalink with data from Wales excluded),[17] and one in each of Denmark,[18, 19] Norway[20, 21] 
and the Netherlands[22] (Table 1). Data sources that involved the linkage of multiple 
databases will be referred to as a single database for the remainder of this paper; for 
example, the Norwegian Medical Birth Registry was linked to the Norwegian Prescription 
Database. A more detailed description of the databases can be found elsewhere.[23] Ethical 
and data access approvals were obtained for each database from the relevant governance 
infrastructures. 
 
--------- Insert Table 1 here --------- 
 
Study population 
All databases followed a common protocol. Within each database pregnancies which started 
and ended between 1 January 2004 and 31 December 2010 were identified (except for 
Denmark and Norway where inclusion dates were 1-Jan-2004 to 31-Dec-2009 and 1-Jul-
2004 to 31-Dec-2010 respectively). Pregnancies were excluded if they did not end in a 
delivery (live/stillbirth) and if the woman was not followed in the database, which captured 
prescription data, for the six months before pregnancy, throughout pregnancy and for at 
least six months following delivery. For each pregnancy ending in a delivery, the start date 
of the pregnancy was identified or estimated based on additional data including gestational 
age at birth and the date of delivery (Table 1). For each pregnancy, the start and end of each 
pregnancy trimester was determined; trimester one was from the start of pregnancy 
through to 90 days gestational age, trimester two was from 91 until 188 days and trimester 
three was from 189 days gestational age until delivery. 
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Exposure 
All prescriptions for AEDs in the 6 months before pregnancy, during pregnancy and in the 6 
months following delivery were identified. In the UK databases this included all AED 
prescriptions issued whilst in the other databases it was only AED prescriptions actually 
dispensed. AEDs were defined as those with an Anatomical Therapeutic Classification (ATC) 
code starting N03A or N05BA09, in addition to N05BA01, N05BA06, N05CD08 and N05CC05 
when prescribed as a non-oral preparation. AEDs identified included, but were not limited 
to, barbexaclone, carbamazepine, clonazepam, diazepam, ethosuxamide, phenobarbital, 
phenytoin, primadone and valproate, categorised as ‘old’ AEDs and felbamate, gabapentin, 
lamotrigine, levetiracetam, oxcarbazepine, pregabalin, tiagabine, topiramate, vigabatrin and 
zonsamide, categorised as ‘newer’ AEDs. A full list of AEDs and their availability in each of 
the regions during the study period can be found in Table S1. Multiple therapy prescribing, 
reflecting either polytherapy or switching, was defined as a prescription for two or more 
different AEDs during a 3-month time period. Prescriptions issued for folic acid (ATC 
B03BB01/B03BB51) were also identified.  
 
Analyses 
The prevalence of prescribing was calculated, for each AED and each database, for the 6 
months leading up to pregnancy, during pregnancy and the 6 months following delivery. The 
AED prescribing prevalence was also calculated for each pregnancy trimester and for two 3-
month time periods both before and after pregnancy and reported per 10,000 deliveries.  
 
Monotherapy and multiple-therapy prescribing were compared between databases. The 
percentage of AED exposed deliveries prescribed specific AEDs and changes in prescribing 
between 2004 and 2009 were evaluated. The percentage of pregnancies where the women 
received only a single AED prescription during the entire 21-month time period was 
determined and maternal age at the start of pregnancy was evaluated stratified by AED. The 
percentage of AED exposed pregnancies where the woman received a co-prescription for 
folic acid, within the same 3-month period, was calculated.  
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Results 
In total, 978,957 eligible women with 1,248,713 deliveries were identified. The mean 
maternal age at the start of pregnancy ranged from 27.6 years in Wales to 32.2 years in 
Emilia Romagna (Table 2). Overall, AED prescribing prevalence during the 6 months before 
pregnancy was 64/10,000 deliveries (CI9562-65) and was lowest in Denmark and highest in 
the UK (Table 2). During pregnancy, the AED prescribing prevalence was 51/10,000 
deliveries (CI9549-52). In all databases, prescribing declined during the first and second 
trimesters of pregnancy (Figure 1). By four to six months post-delivery, AED prescribing had 
returned to pre-pregnancy levels in the Dutch and both UK databases (Figure 1), whilst in 
the Danish, Italian and Norwegian databases AED prescribing was 10% to 20% lower than 
during the four to six months before pregnancy. When looking at the entire 21-month time 
period, the prevalence of prescribing was highest in the Tuscany database (Table 2). The 
percentage of pregnancies where the woman received only a single AED prescription during 
the entire 21-month time period was lowest in Denmark (17.4%) and highest in Tuscany 
(43.7%). Variations were observed in the time period when the woman was identified as 
receiving an AED prescription. In Denmark, Norway, Wales and the rest of the UK, 
approximately 75-79% of women identified as receiving an AED prescription received one 
during the 6 months before pregnancy, compared with 60-61% in Tuscany and the 
Netherlands (Table S2). Subsequently Tuscany and the Netherlands had a larger percentage 
of women who only received a prescription during the 6 months following the end of 
pregnancy. The percentage of women who received a prescription during pregnancy but not 
during the 6 months before pregnancy ranged from 8.4% in the UK to 15.1% in Tuscany. 
 
---------- Insert Table 2 and Figure 1 here --------- 
 
The percentage of AED exposed deliveries accounted for by the 5 most commonly 
prescribed AEDs, during each of the time periods, is shown in Figure 2. In the Danish and 
Norwegian databases, lamotrigine was clearly the drug of choice and the Danish database 
had the lowest levels of carbamazepine and valproate prescribing during pregnancy (Figure 
2). In the UK databases lamotrigine was also the most frequently prescribed AED, followed 
more closely by carbamazepine and valproate. The trends observed in the Italian databases 
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differed from those observed in Northern Europe, with carbamazepine, valproate and 
phenobarbital being more popular. Differences were observed between the two Italian 
databases, with phenobarbital being the most popular during pregnancy in Tuscany whilst in 
Emilia Romagna it was carbamazepine. Carbamazepine was the most commonly prescribed 
AED in the Netherlands, although here the prescribing of lamotrigine did increase during 
early pregnancy.  No clear trends were observed, in any database, in relation to choice of 
AED and maternal age.  
 
----------- Insert Figure 2 here ---------- 
 
Of the newer AEDs, lamotrigine was the most commonly prescribed in all regions. Denmark 
was the only region where the percentage of oxcarbazepine exposures was higher than 
carbamazepine. In all regions, the use of topiramate, gabapentin and pregabalin declined 
during pregnancy whilst the use of lamotrigine and levetiracetam increased. 
The majority of women were treated with AED monotherapy. In Wales, approximately 30% 
of AED users received prescriptions for two or more different AEDs during a 3-month time 
period whilst elsewhere it was between 10% and 20% (Figure S1). Prescribing of valproate 
during the first trimester in addition to another AED ranged from 2.0% (CI951.2-2.7%) of all 
AED exposed pregnancies in Denmark to 4.3% (CI952.8-5.9%) in Tuscany. 
 
During the study period, a steady increase in the percentage of pregnancies where the 
woman received a prescription for lamotrigine during pregnancy was observed in Denmark, 
Tuscany and the Netherlands (Figure S2). In all regions, with the exception of Emilia 
Romagna, the proportion of AED exposed pregnancies receiving a prescription for valproate 
declined, whilst carbamazepine prescribing also declined in Denmark, Norway and Wales. 
During pregnancy, in Denmark and the UK a steady increase was observed in pregabalin and 
levetiracetam prescribing, whilst in Tuscany a decline in gabapentin and an increase in 
topiramate was observed. In the UK and Danish databases an increase in topiramate 
prescribing was observed between 2004 and 2007 followed by a decline from 2008.  
 
Standard dose folic acid (≤0.5mg) was available over-the-counter in all regions, whereas 
high dose folic acid (>0.5mg) was only available on prescription. In Norway, the higher dose 
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prescribed was typically 1mg whilst elsewhere it was 5mg. No folic acid data were available 
for this study for Denmark. During the 3 months before pregnancy, the percentage of AED 
exposed pregnancies where the woman received a high dose folic acid prescription ranged 
from 1.0% (CI950.3-1.8%) in Emilia Romagna to 33.5% (CI9528.7-38.4%) in Wales. During the 
first trimester these increased to 6.1% (CI954.1-8.2%) and 66.3% (CI9561.2-71.4%) 
respectively (Figure 3a). In Tuscany, co-prescribing of folic acid was largely not until after the 
start of pregnancy and usually at the lower ≤0.5mg dose (Figure 3b). During the 3 months 
before pregnancy fewer than 50% of women received a prescription for folic acid of any 
dose. 
 
---------- Insert Figure 3 here ----------- 
 
 
Discussion 
Geographic variations were identified in the prevalence of AED prescribing and the AEDs 
most commonly prescribed before, during and after pregnancy. In all databases, prescribing 
declined during pregnancy. In Denmark, Norway and the UK, lamotrigine was clearly the 
AED of choice whilst in the Netherlands and Italian regions the older AEDs were more 
popular. Prescribing of folic acid during the 3 months before pregnancy was below 50% in all 
databases.  
 
This study captured almost 11,000 deliveries, between 2004 and 2010, where the woman 
received an AED prescription during pregnancy or in the 6 months either side of pregnancy. 
Prescribing information was recorded independently of the women, removing recall bias; 
however no data were available on adherence and whether the woman actually took the 
medicine. In the UK databases, data were based on prescriptions issued in primary care 
whereas in other regions it was prescriptions dispensed by a pharmacist. Some women who 
are issued prescriptions may choose not to have them dispensed; this is less likely for AEDs 
prescribed for epilepsy, than for other indications, owing to the need to maintain good 
seizure control. None of the databases captured medicines given directly to the patient 
during a hospital stay. In Denmark, Norway and the Netherlands all other AED prescribing 
was captured. In the UK databases, prescriptions initiated by a specialist in a hospital 
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outpatient department and private prescriptions were rarely recorded; these numbers were 
likely to be small as most subsequent repeat prescribing will have been undertaken in 
primary care and private practice is limited. In Italy, only prescriptions reimbursed by the 
Italian healthcare system were captured, this excluded private prescriptions and the 
majority of prescriptions issued in secondary care, unless following the appointment the 
patient took the prescription to their GP and the GP prescribed it. In Emilia Romagna, 
prescriptions dispensed at a hospital pharmacy were also not captured during the study 
period; based on data from 2011, when this data started to be included in the database, the 
percentage of non-private prescriptions from a hospital pharmacy was approximately 30% 
of all AED prescriptions (A Puccini - personal correspondence). Increased availability of 
hospital dispensing data would allow maternal exposure to AEDs to be measured more 
accurately. 
 
When exploring exposure patterns for women receiving prescriptions for more than one 
AED during a 3-month time period, this study did not differentiate between those who were 
taking them concomitantly and those switching between products. This study looked at the 
time period when a prescription was issued/dispensed, irrespective of duration. It is 
possible that some women will have received a prescription during one 3-month time 
period and continued taking it during the following period, even though they did not receive 
a further prescription, which may have resulted in some exposure status misclassification. 
For chronic conditions, such as epilepsy, this is likely to have had less of an impact than for 
episodic conditions. Bias may also have been introduced if the average prescription duration 
differed between regions, as this could have resulted in women in regions with a longer 
prescription duration (3 months or greater) contributing exposure information to fewer 
time periods than women in regions with a shorter prescription duration, even though they 
were continuously exposed.  
 
For all deliveries, this study looked at prescribing during pregnancy as well as prescribing 
during the 6 months before and after pregnancy. In approximately 6.5% of pregnancies, part 
of the 6-month time period following a pregnancy overlapped to some extent with part of 
the 6-month time period before the start of a subsequent pregnancy or during part of the 
subsequent pregnancy itself. This will not have influenced the choice of prescribing during 
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the actual pregnancy itself but for a small number of pregnancies exposure during part of 
the 6-months following delivery may actually have been influenced by the fact that the 
mother had become pregnant. This study was not able to examine the clinical indication for 
prescribing as this was not fully available within the databases; this is a common limitation 
of electronic healthcare and claims databases. AEDs may be prescribed for several 
indications other than epilepsy, including psychiatric conditions where doses may be lower 
and polytherapy with other medicine classes is common. For AEDs prescribed to treat non-
epilepsy indications it is possible that the choice of AED may have been selected for their 
relatively low potential for drug interactions rather than their pharmacodynamic profile. The 
regional variation observed in the time at which women received an AED prescription may 
suggest differences in the indication for prescribing, with those regions with a higher 
percentage of women receiving a prescription only during the 6 months after pregnancy, 
and not before or during pregnancy, indicating a greater level of prescribing for non-
epilepsy indications. There is a need for more data sources that contain data on the 
indication for prescribing, especially for safety studies where there is the possibility of 
confounding by indication.  
 
The popularity of the newer AEDs observed in Denmark was in line with another study, 
published by the European and International Registry of Antiepileptic drugs in Pregnancy 
(EURAP).[24] The use of lamotrigine in Norway was found to be higher in our study than the 
EURAP study, although this is likely due to the EURAP study covering an earlier time period 
(1999-2005). The lower use of the newer AEDs and higher use of phenobarbital in the Italian 
databases was in line with the EURAP study[24]  and also with two Italian studies examining 
AED prescribing among the general population.[25-27] In our study population, we did not 
observe a similarly high prescribing rate of gabapentin in Italy,[25, 26] which is likely because 
this is most commonly prescribed for neuropathic pain in women older than childbearing 
age.[27] In Denmark, the higher use of oxcarbazepine is likely to reflect the fact that it 
became available in 1980,[28] whilst in other regions it was not until the 1990s. Our study had 
the strength of being population-based whilst pregnancy registry studies, such as those of 
EURAP,[24] reflect a sample of women who have self-enrolled or been enrolled by healthcare 
professionals. This selective enrolment has the potential to result in an over-representation 
of women taking newer AEDs or women with more severe medical conditions and may 
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mean their findings are not generalizable to all AED users. The AED utilisation figures for the 
UK databases during pregnancy were comparable to those of another study carried out in 
the UK using The Health Improvement Network database.[29]  The prescribing of AEDs in all 
regions was lower than those reported in the United States, where a study evaluating 
administrative health plan data reported that for approximately 2% of deliveries between 
2001 and 2007 the woman received at least one AED prescription during pregnancy or the 
60 days before pregnancy.[30] In the US study, psychiatric conditions and pain disorders were 
reported to be more common indications for AED prescribing than epilepsy.[30]  
 
The prescribing guidelines for all countries recommended that women taking AED therapy, 
who are considering becoming pregnant, aim for monotherapy treatment at the lowest 
effective dose.[10, 31-34] All guidelines acknowledged the increased risks of some major 
congenital anomalies and neurodevelopmental problems associated with valproate 
exposure during pregnancy[4, 35] and the increased risk of neural tube defects associated 
with carbamazepine.[3] It is therefore unclear what is continuing to drive the higher use of 
carbamazepine and valproate in Italy. The Italian guidelines were the only ones not to refer 
to an increased risk of congenital anomalies associated with phenobarbital. Two studies 
have shown phenobarbital to be one of the most commonly prescribed AEDs in Italy 
generally, at least until 2005.[25, 26] In Italy, due to the lack of conclusive evidence, until 
recently, of the teratogenicity of phenobarbital,[36] it was generally not withdrawn in women 
considering becoming pregnant. Italian neurologists would rather advise women to switch 
to phenobarbital from drugs known to be teratogenic (i.e. valproate) or those where little 
information was known, such as the newer AEDs (B Mostacci - personal correspondence). 
The findings of this study suggest that although the use of phenobarbital has declined over 
time, this practice may still be taking place. Although lamotrigine is demonstrating a better 
safety profile, in terms of tolerability and the risk of congenital anomalies in the offspring, 
the changes in endocrine and electrolyte balance and pharmacokinetics that occur in 
pregnancy can increase the risk of seizures[37, 38] and it is possible that these potential risks 
are perceived differently in different regions. Differences observed may also reflect 
differences in prescribing guidelines, the age of women when starting treatment, local 
custom and practice, costs of AEDs, timing of AED introduction to the market, drug 
promotion[24] and the type of prescriber.[39]  
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During the study period in Denmark, Italy and the UK, it was recommended that all women 
prescribed AEDs took high dose folic acid (4-5mg) before pregnancy, with continuation into 
the first trimester.[10, 31, 40] Folic acid supplementation was recommended at a standard 
0.5mg dose in the Netherlands. In Norway, a minimum of 0.4mg was stated with a higher 
dose (4mg) recommended for women prescribed valproate or carbamazepine. Despite 
these recommendations, we found no evidence that co-prescribing of folic acid was usual 
practice during the pre-conception period. It is possible that some women may have 
purchased standard dose folic acid without a prescription which would not have been 
captured in the databases but this would not have given the recommended higher dose. 
Preconception care to review medication is increasingly being recommended and organised 
for women with epilepsy, while the situation regarding psychiatric care is less clear.  
Conclusion 
The regional differences in prescribing patterns identified suggest different use, knowledge 
or interpretation of the scientific evidence base, and are unlikely to reflect informed choice 
of women. The decline in AED prescribing during pregnancy and the low co-prescribing of 
folic acid suggest that many pregnancies were either unplanned or that full preconception 
care, including review of optimal AED medications for pregnancy, was not received by many 
women. Further research into the indications for which specific AEDs are prescribed during 
pregnancy is needed. This may help identify areas where more could be done to better 
inform clinicians and women of childbearing age taking AEDs of the need to plan their 
pregnancy and seek and receive complete preconception care.  
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Table 1  Overview of databases contributing to the study 
 
Country/Region 
 
Netherlands 
 
Denmark 
 
Norway Italy - 
Emilia Romagna 
 Italy -   
Tuscany 
United Kingdom1 
 
Wales 
 
Involves database linkage No Yes Yes Yes Yes No Yes
2 
Coverage 
 
Regional  National National Regional Regional ~8.5% sample of UK 
population 
~40% sample of GP 
practices in Wales 
Population base 500,000  ~5,000,000 ~4,800,000 4,200,000 3,700,000  ~5,000,0003 2,000,000 
Database for live & 
stillbirth pregnancy 
identification 
IADB.nl  
database  
Danish National  
Birth Registry 
 
Medical  
Birth Registry  
of Norway 
Certificate of Delivery 
Assistance (CeDAP) 
 
Certificate of Delivery 
Assistance (CeDAP) 
Hospital Discharges 
Registry 
Clinical Practice 
Research Datalink 
 (CPRD)4 
National Community 
Child Health Database 
(NCCHD) 
Database for medicine  
use data 
 
IADB.nl  
 database 
Danish  
Prescription Registry 
Norwegian Precsription 
Database 
Emilia-Romagna 
Prescription Database 
(ERPD) 
Tuscany Prescription 
Database 
(TPD) 
Clinical Practice 
Research Datalink 
 
The General Practice 
(GP) Dataset 
Source for medicine use 
data 
Pharmacy 
dispensing 
Pharmacy 
dispensing 
Pharmacy  
dispensing 
Pharmacy  
dispensing5 
Pharmacy dispensing  
and Healthcare Facilities 
Dispensing5 
GP practice 
prescribing 
GP practice 
prescribing 
 
Capture GP prescribing 
 
Yes Yes Yes Yes 
 
Yes 
 
Yes 
 
Yes 
 
Capture hospital 
inpatient prescribing 
No 
 
No 
 
No No 
 
No 
 
Some 
 
Some 
 
Date of last menstrual 
period recorded 
Estimated 
for all 
Calculated from 
gestational age 
Yes Calculated from 
gestational age 
Calculated from 
gestational age 
Yes for 40% 
Estimated for 60% 
Yes for 80% 
Estimated for 20% 
Recommendations for 
folic acid use in women 
prescribed AEDs planning 
a pregnancy 
 
 
Standard dose 
(0.5mg) before 
pregnancy and 
during first 
trimester. 
High dose (5mg) 
before pregnancy 
and during first 
trimester 
Standard dose (0.4mg) 
before pregnancy and 
during first trimester. High 
dose (1.0-4.0mg) for 
women prescribed valproic 
acid or carbamazepine.  
High dose (4-5mg) 
before pregnancy and 
during first trimester 
High dose (4-5mg) 
before pregnancy and 
during first trimester 
High dose (5mg) 
before pregnancy and 
during first trimester 
High dose (5mg) 
before pregnancy and 
during first trimester 
Capture standard dose 
folic acid  
No No Most Some when 
 prescribed 
Some when  
prescribed 
Some when 
prescribed 
Some when 
prescribed 
Capture high dose folic 
acid   
Yes Yes Yes Yes Yes Yes Yes 
                                                          
   1  Excluding practices in Wales to avoid duplication of pregnancies in the database contributing data for Wales 
  2  Secure Anonymised Information Linkage (SAIL) databank 
  3  The size of the population captured by the CPRD has grown steadily over time and was approximately 5.0 million in May 2012 
  4  Previously the General Practice Research Database (GPRD) 
  5  Only products reimbursed by the Italian National Health Service 
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Table 2 Prevalence of AED prescribing in women with a delivery between 2004 and 2010  
 
 
Country/region 
 
Number of 
eligible 
deliveries in 
entire 
cohort 
 
Mean maternal 
age at 
pregnancy start 
for entire 
cohort 
AED prescription during 
 
the 6 months before 
pregnancy 
 
any of the pregnancy 
trimesters  
 
the 6 months 
following 
pregnancy  
 
any of the time periods  
 N        Years   SD* Per 
10,000 
(95% CI) Per 
10,000 
(95% CI) Per 
10,000 
(95% CI) N Per 
10,000 
(95% CI) 
Denmark± 324,134 30.0    [4.9] 54 (51 - 57) 46 (44 - 49) 46 (44 - 48) 2,207 68 (65 - 71) 
Italy – Tuscany 157,916 31.8    [4.9] 77 (73 - 82) 56 (52 - 59) 65 (61- 69) 2,014 128 (122 - 133) 
Italy – Emilia Romagna 149,485 32.2    [5.0] 62 (58 - 66) 44 (41 - 48) 48 (44 - 51) 1,357 91 (86 - 96) 
Norway≠ 330,758 29.7    [5.1] 64 (61 - 67) 49 (47 - 52) 50 (47 - 52) 2,815 85 (82 - 88) 
The Netherlands 14,725 29.4    [4.8] 56 (44 - 68) 43 (33 - 54) 51 (39 - 62) 119 81 (66 - 95) 
United Kingdom* 207,570 30.1    [6.0] 68 (64 - 71) 58 (55 - 62) 66 (62 - 69) 1,874 90 (86 - 94) 
Wales 64,125 27.6    [6.1] 66 (60 - 73) 60 (54 - 66) 64 (58 - 71) 572 89 (82 - 96) 
Total across countries 1,248,713  64 (62 - 65) 51 (49 - 52) 54 (52 - 55) 10,958 88 (86 - 89) 
† Standard deviation 
± 1 January 2004 – 31 December 2009 
≠  1 July 2004 – 31 December 2010 
* Excluding Wales to avoid duplication of pregnancies in the Welsh SAIL databank 
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Figure titles 
 
 
Figure 1 Prevalence of AED prescribing, per 10,000 deliveries, between 2004 and 2010  
 
 
Figure 2 Percentage of all AED exposed deliveries prescribed the 5 most commonly 
prescribed AEDs in each region between 2004 and 2010 
 
 
Figure 3 Percentage of AED exposed deliveries where the women was co-prescribed folic 
acid during the time period of interest  
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Figure 1  
 
 
* excluding Wales 
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Figure 2 
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Figure 3 
 
a) high dose folic acid (>0.5mg†) 
 
* excluding Wales. † In Norway this was almost entirely for 1mg whilst in other countries it was largely 5mg 
 
 
b) standard dose folic acid (≤0.5mg) 
  
* excluding Wales 
Standard dose folic acid purchased over-the-counter without a prescription was not captured in any region, 
however, prescriptions issued for standard dose folic acid were captured in all regions apart from Norway. No 
folic acid data were available for this study from Denmark.  
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Figures for online only 
 
Figure S1 Percentage of AED exposed pregnancies where the woman was prescribed an AED 
as monotherapy  
 
Figure S2 Changes in AED prescribing during pregnancy between 2004 and 2009 for the 6 
most commonly prescribed AEDs in 2009 
 
 
 
Table for online only 
 
Table S1 Availability of AEDs during the study period in each region 
 
Table S2 Percentage of pregnancies where the woman received her first AED prescription 
during each of the time periods of interest 
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Figure S1 
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Figure S2 
   
 
 
 
0
10
20
30
40
50
60
70
2004 2005 2006 2007 2008 2009
%
 o
f 
A
ED
 e
xp
o
se
d
 d
e
liv
e
ri
e
s
Year of start of pregnancy
Denmark
0
10
20
30
40
50
60
70
2004 2005 2006 2007 2008 2009
%
 o
f 
A
ED
 e
xp
o
se
d
 d
e
liv
e
ri
e
s
Year of start of pregnancy
Norway
0
10
20
30
40
50
60
70
2004 2005 2006 2007 2008 2009%
 o
f 
A
ED
 e
xp
o
se
d
 d
e
liv
e
ri
e
s
Year of start of pregnancy
United Kingdom*
0
10
20
30
40
50
60
70
2004 2005 2006 2007 2008 2009%
 o
f 
A
ED
 e
xp
o
se
d
 d
e
liv
e
ri
e
s
Year of start of pregnancy
Wales
0
10
20
30
40
50
60
70
2004 2005 2006 2007 2008 2009%
 o
f 
A
ED
 e
xp
o
se
d
 d
e
liv
e
ri
e
s
Year of start of pregnancy
Tuscany
0
10
20
30
40
50
60
70
2004 2005 2006 2007 2008 2009
%
 o
f 
A
ED
 e
xp
o
se
d
 d
e
liv
e
ri
e
s
Year of start of pregnancy
Emilia Romagna
0
10
20
30
40
50
60
70
2004 2005 2006 2007 2008 2009
%
 o
f 
A
ED
 e
xp
o
se
d
 d
e
liv
e
ri
e
s
Year of start of pregnancy
The Netherlands
Carbamazepine
Lamotrigine
Valproate
Topiramate
Gabapentin
Levetiracetam
Phenobarbital
Pregabalin
 
 
28 
 
Table S1 Availability of AEDs during the study period in each region 
  Available during the study period  
ATC code Name 
D
e
n
m
ar
k 
Em
ili
a 
R
o
m
ag
n
a
 
N
o
rw
ay
 
Th
e
 N
e
th
e
rl
an
d
s 
Tu
sc
an
y 
U
n
it
e
d
 K
in
gd
o
m
 
W
al
e
s 
N03AA01 Methylphenobarbital N N N N N N N 
N03AA02 Phenobarbital Y Y Y Y Y Y Y 
N03AA03 Primidone Y Y Y6  Y Y7 Y Y 
N03AA04 Barbexaclone N Y N  N Y N N 
N03AA30 Metharbital Y N N  N N N N 
N03AB01 Ethotoin N N N Y N N N 
N03AB02 Phenytoin Y Y Y Y Y Y Y 
N03AB03 Amino (diphenylhydantoin) valeric acid N N N  N N N N 
N03AB04 Mephenytoin N N N  N N N N 
N03AB05 Fosphenytoin Y Y8 N  N N Y Y 
N03AB52 Phenytoin combinations N N N  N Y N N 
N03AB54 Mephenytoin combinations N N N  N N N N 
N03AC01 Paramethadione N N N  N N N N 
N03AC02 Trimethadione N N N  N N N N 
N03AC03 Ethadione N N N  N N N N 
N03AD01 Ethosuximide  Y Y N  Y Y Y Y 
N03AD02 Phensuximide N N N  N N N N 
N03AD03 Mesuximide N N N  N N N N 
N03AD51 Ethosuximide combinations N N N  N N N N 
N03AF01 Carbamazepine  Y Y Y Y Y Y Y 
N03AF02 Oxcarbazepine  Y Y Y Y Y Y Y 
N03AF03 Rufinamide  Y Y9 N  YV Y10 Yv Yv 
N03AF04 Eslicarbazepine  Y N Y*11  Yvii N Y12 Yvii 
N03AG01 Valproic acid Y Y Y Y Y Y Y 
N03AG02 Valpromide  N Y N  N Y N N 
N03AG03 Aminobutyric acid  N Y N  N Y N N 
N03AG04 Vigabatrin  Y Y Y Y Y Y Y 
N03AG05 Progabide  N N N  N N N N 
N03AG06 Tiagabine  N Y N  N Y Y Y 
N03AX03 Sultiame  N N N  N N N N 
                                                          
6     2004-2007 
7    From 2005 
8   Hospital only 
9   From 2008 
10    From 2007 
11   From 2010 
12  From 2009 
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N03AX07 Phenacemide  N N N  N N N N 
N03AX09 Lamotrigine  Y Y Y Y Y Y Y 
N03AX10 Felbamate  N N Y13  Yix Y Y*14 Yix 
N03AX11 Topiramate  Y Y Y Y Y Y Y 
N03AX12 Gabapentin  Y Y Y Y Y Y Y 
N03AX13 Pheneturide  N N N  N N N N 
N03AX14 Levetiracetam  Y Y Y Y Y Y Y 
N03AX15 Zonisamide  Y15 Y Y  Y Yx Y Y 
N03AX16 Pregabalin  Y Y Y Y Y Y Y 
N03AX17 Stiripentol  Y16 Y*17 N  Y N N N 
N03AX18 Lacosamide  Y18 Y N  Y Yxiii Y Y 
N03AX19 Carisbamate  N N N N N N N 
N03AX21 Retigabine  N N N Y N N N 
N03AX30 Beclamide  N N N  N N N N 
N05BA01 Diazepam – rectal and parenteral only N Y Y Y Y Y Y 
N05BA06 Lorazepam - injection only N Y19 N Y Y Y Y 
N05BA09 Clobazam Y Y Y  Y Y Y Y 
N05CD08 Midazolam – buccal and nasal only N Y Y20  N N Y Y 
N03AE01 Clonazepam  Y Y Y  Y Y Y Y 
N05CC05 Paraldehyde - rectum only N N N  N N Y Y 
 
  
                                                          
13 From 2005 
14  From 2009 
15   From 2005 
16   From 2007 
17  From 2009, hospital prescribing only 
18 From 2008 
19 Hospital prescribing only 
20  From 2006-2007 
 
 
 
 
30 
 
Table S2 
 
  First AED prescription during   
 Country/region 
6 months 
pre-preg 
During 
preg 
6 months 
post preg Total AED 
  N % N % N %   
Denmark 1750 79.3 203 9.2 254 11.5 2,207 
Italy – Tuscany 1220 60.6 304 15.1 490 24.3 2,014 
Italy – Emilia Romagna 933 68.8 182 13.4 242 17.8 1,357 
Norway≠ 2124 75.5 312 11.1 379 13.5 2,815 
The Netherlands 73 61.3 12 10.1 34 28.6 119 
United Kingdom 1409 75.2 157 8.4 308 16.4 1,874 
Wales  426 74.5 59  10.3 87  15.2 572 
 
 
 
